Redeye was hoping for higher sales in the second quarter.
Redeye comments on Sleep Cycle's Q2 2024 report, which came in slightly better on sales and EBIT tha...
We upgrade adjusted EBIT by 2-3% for 2024-26E, encouraged by a continued healthy North American mark...
- Q2 sales EUR 43m, -7% y-o-y, order intake EUR 40m, +11% y-o-y - Minor adjustments to '24-'26 estim...
- 3% organic sales growth y-o-y - Lower profitability than we expected - Adj.
Kvartalet belastades av en svagare konjunktur och lägre volymer för Hanzas kunder.
Focus has reverted to project and service operations.
- Orders -6% vs ABGSCe, sales in line, EBIT 31% above - Adj.
- EBIT SEK 30m vs. ABGSCe SEK 63m; Q3e likely better - Pulp prices at ATHs, but may have peaked shor...
Underliggande portföljbolagen utvecklas väl även om försäljningen av Gett och en viss multipelnedgån...
Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer cen...
- EBIT SEK 30m vs. ABG SEK 63m - Q3 likely stronger — Rottneros Mill maintenance moved to Q4 - Confe...
- Organic growth of 9% vs. cons. 9.5% - Adj. EBITA SEK 141m, 3% below consensus - Gross margin gains...
DT reports Q2 results on Aug 6. We make no big estimate changes, while earnings multiples aren’t yet...
Redeye updates its estimates and valuation following Mentice’s Q2 2024 report.
- 6% organic growth despite headwinds in major markets - Strong margins highlight low guidance into ...
- Minor positive estimate revisions - Expect primarily volume-driven growth - FVR of SEK 20-35 reite...
- Q2: Adj. EBITDA of NOK 1m - New targets more achievable — sales +22% in '25e vs '23 - Customers re...
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with a more in-de...
Redeye remains confident on the case, despite the unexpected news of CEO Axel Berntsson leaving the ...
